Current prospects for mRNA gene delivery

European Journal of Pharmaceutics and Biopharmaceutics

Volumn 71, Issue 3, 2009, Pages 484-489

  Yamamoto, Ayako ^a   Kormann, Michael ^a   Rosenecker, Joseph ^a   Rudolph, Carsten ^a,b  

^a UNIVERSITY OF MUNICH   (Germany)

^b FREIE UNIVERSITÄT BERLIN   (Germany)

Author keywords

Gene delivery; Gene therapy; mRNA

Indexed keywords

1,2 DIOLEOYL 3 TRIMETHYLAMMONIOPROPANE; ARYLDIALKYLPHOSPHATASE 1; CANCER VACCINE; DIETHYLAMINOETHYLDEXTRAN; INTERLEUKIN 2; LIPOFECTIN; LIPOPLEX; LIPOSOME; MELAN A; MESSENGER RNA; PLASMID DNA; POLYETHYLENEIMINE; PROSTATE SPECIFIC ANTIGEN; RECOMBINANT VACCINE; SOMATOMEDIN C; TOLL LIKE RECEPTOR; VIRUS VECTOR;

ARTERY INTIMA PROLIFERATION; BACTERIOPHAGE; BRAIN TUMOR; CANCER IMMUNOTHERAPY; CPG ISLAND; CYTOKINE RELEASE; CYTOTOXIC T LYMPHOCYTE; DENDRITIC CELL; ELECTROPORATION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; IMMUNE RESPONSE; IMMUNOGENICITY; INFLAMMATION; MELANOMA B16; MUSCLE REGENERATION; NONHUMAN; NONVIRAL GENE DELIVERY SYSTEM; PROSTATE TUMOR; REVIEW; RNA CAPPING; RNA STRUCTURE; SEMLIKI FOREST ALPHAVIRUS; SINDBIS VIRUS; TRANSGENE; VENEZUELAN EQUINE ENCEPHALOMYELITIS ALPHAVIRUS; VIRAL GENE DELIVERY SYSTEM;

ANIMALS; BIOLOGICAL TRANSPORT; DNA; GENE THERAPY; GENE TRANSFER TECHNIQUES; GENETIC VECTORS; HUMANS; PLASMIDS; RNA, MESSENGER;

EID: 60749083781     PISSN: 09396411     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejpb.2008.09.016     Document Type: Review

References (99)

1. Mockey M., Bourseau E., Chandrashekhar V., Chaudhuri A., Lafosse S., Le Cam E., Quesniaux V.F., Ryffel B., Pichon C., and Midoux P. mRNA-based cancer vaccine: prevention of B16 melanoma progression and metastasis by systemic injection of MART1 mRNA histidylated lipopolyplexes. Cancer Gene. Ther. 14 (2007) 802-814
2. Conry R.M., LoBuglio A.F., Wright M., Sumerel L., Pike M.J., Johanning F., Benjamin R., Lu D., and Curiel D.T. Characterization of a messenger RNA polynucleotide vaccine vector. Cancer Res. 55 (1995) 1397-1400
3. Martinon F., Krishnan S., Lenzen G., Magne R., Gomard E., Guillet J.G., Levy J.P., and Meulien P. Induction of virus-specific cytotoxic T lymphocytes in vivo by liposome-entrapped mRNA. Eur. J. Immunol. 23 (1993) 1719-1722
4. Boczkowski D., Nair S.K., Snyder D., and Gilboa E. Dendritic cells pulsed with RNA are potent antigen-presenting cells in vitro and in vivo. J. Exp. Med. 184 (1996) 465-472
5. Carralot J.P., Probst J., Hoerr I., Scheel B., Teufel R., Jung G., Rammensee H.G., and Pascolo S. Polarization of immunity induced by direct injection of naked sequence-stabilized mRNA vaccines. Cell. Mol. Life Sci. 61 (2004) 2418-2424
6. Hoerr I., Obst R., Rammensee H.G., and Jung G. In vivo application of RNA leads to induction of specific cytotoxic T lymphocytes and antibodies. Eur. J. Immunol. 30 (2000) 1-7
7. Heiser A., Coleman D., Dannull J., Yancey D., Maurice M.A., Lallas C.D., Dahm P., Niedzwiecki D., Gilboa E., and Vieweg J. Autologous dendritic cells transfected with prostate-specific antigen RNA stimulate CTL responses against metastatic prostate tumors. J. Clin. Invest. 109 (2002) 409-417
8. Ponsaerts P., Van Tendeloo V.F., and Berneman Z.N. Cancer immunotherapy using RNA-loaded dendritic cells. Clin. Exp. Immunol. 134 (2003) 378-384
9. Krieg A.M. CpG motifs in bacterial DNA and their immune effects. Annu. Rev. Immunol. 20 (2002) 709-760
10. Arthur J.F., Butterfield L.H., Roth M.D., Bui L.A., Kiertscher S.M., Lau R., Dubinett S., Glaspy J., McBride W.H., and Economou J.S. A comparison of gene transfer methods in human dendritic cells. Cancer Gene. Ther. 4 (1997) 17-25
11. Diebold S.S., Kursa M., Wagner E., Cotten M., and Zenke M. Mannose polyethylenimine conjugates for targeted DNA delivery into dendritic cells. J. Biol. Chem. 274 (1999) 19087-19094
12. Diebold S.S., Lehrmann H., Kursa M., Wagner E., Cotten M., and Zenke M. Efficient gene delivery into human dendritic cells by adenovirus polyethylenimine and mannose polyethylenimine transfection. Hum. Gene. Ther. 10 (1999) 775-786
13. Strobel I., Berchtold S., Gotze A., Schulze U., Schuler G., and Steinkasserer A. Human dendritic cells transfected with either RNA or DNA encoding influenza matrix protein M1 differ in their ability to stimulate cytotoxic T lymphocytes. Gene Ther. 7 (2000) 2028-2035
14. Mockey M., Goncalves C., Dupuy F.P., Lemoine F.M., Pichon C., and Midoux P. mRNA transfection of dendritic cells: synergistic effect of ARCA mRNA capping with Poly(A) chains in cis and in trans for a high protein expression level. Biochem. Biophys. Res. Commun. 340 (2006) 1062-1068
15. Holtkamp S., Kreiter S., Selmi A., Simon P., Koslowski M., Huber C., Tureci O., and Sahin U. Modification of antigen-encoding RNA increases stability, translational efficacy, and T-cell stimulatory capacity of dendritic cells. Blood 108 (2006) 4009-4017
16. Elango N., Elango S., Shivshankar P., and Katz M.S. Optimized transfection of mRNA transcribed from a d(A/T)100 tail-containing vector. Biochem. Biophys. Res. Commun. 330 (2005) 958-966
17. Rozenski J., Crain P.F., and McCloskey J.A. The RNA Modification Database: 1999 update. Nucleic Acids Res. 27 (1999) 196-197
18. Ishii K.J., and Akira S. TLR ignores methylated RNA?. Immunity 23 (2005) 111-113
19. Kariko K., Ni H., Capodici J., Lamphier M., and Weissman D. mRNA is an endogenous ligand for Toll-like receptor 3. J. Biol. Chem. 279 (2004) 12542-12550
20. Kariko K., Buckstein M., Ni H., and Weissman D. Suppression of RNA recognition by Toll-like receptors: the impact of nucleoside modification and the evolutionary origin of RNA. Immunity 23 (2005) 165-175
21. Banerjee A.K. 5′-terminal cap structure in eucaryotic messenger ribonucleic acids. Microbiol. Rev. 44 (1980) 175-205
22. Jackson R.J. Cytoplasmic regulation of mRNA function: the importance of the 3′ untranslated region. Cell 74 (1993) 9-14
23. Pasquinelli A.E., Dahlberg J.E., and Lund E. Reverse 5′ caps in RNAs made in vitro by phage RNA polymerases. RNA 1 (1995) 957-967
24. Cai A., Jankowska-Anyszka M., Centers A., Chlebicka L., Stepinski J., Stolarski R., Darzynkiewicz E., and Rhoads R.E. Quantitative assessment of mRNA cap analogues as inhibitors of in vitro translation. Biochemistry 38 (1999) 8538-8547
25. Marcotrigiano J., Gingras A.C., Sonenberg N., and Burley S.K. Cocrystal structure of the messenger RNA 5′ cap-binding protein (eIF4E) bound to 7-methyl-GDP. Cell 89 (1997) 951-961
26. Matsuo H., Li H., McGuire A.M., Fletcher C.M., Gingras A.C., Sonenberg N., and Wagner G. Structure of translation factor eIF4E bound to m7GDP and interaction with 4E-binding protein. Nat. Struct. Biol. 4 (1997) 717-724
27. Stepinski J., Waddell C., Stolarski R., Darzynkiewicz E., and Rhoads R.E. Synthesis and properties of mRNAs containing the novel "anti-reverse" cap analogs 7-methyl(3′-O-methyl)GpppG and 7-methyl (3′-deoxy)GpppG. RNA 7 (2001) 1486-1495
28. Jemielity J., Fowler T., Zuberek J., Stepinski J., Lewdorowicz M., Niedzwiecka A., Stolarski R., Darzynkiewicz E., and Rhoads R.E. Novel "anti-reverse" cap analogs with superior translational properties. RNA 9 (2003) 1108-1122
29. Kalek M., Jemielity J., Darzynkiewicz Z.M., Bojarska E., Stepinski J., Stolarski R., Davis R.E., and Darzynkiewicz E. Enzymatically stable 5′ mRNA cap analogs: synthesis and binding studies with human DcpS decapping enzyme. Bioorg. Med. Chem. 14 (2006) 3223-3230
30. Grudzien E., Kalek M., Jemielity J., Darzynkiewicz E., and Rhoads R.E. Differential inhibition of mRNA degradation pathways by novel cap analogs. J. Biol. Chem. 281 (2006) 1857-1867
31. Grudzien-Nogalska E., Jemielity J., Kowalska J., Darzynkiewicz E., and Rhoads R.E. Phosphorothioate cap analogs stabilize mRNA and increase translational efficiency in mammalian cells. RNA 13 (2007) 1745-1755
32. Gallie D.R. A tale of two termini: a functional interaction between the termini of an mRNA is a prerequisite for efficient translation initiation. Gene 216 (1998) 1-11
33. Coller J., and Parker R. Eukaryotic mRNA decapping. Annu. Rev. Biochem. 73 (2004) 861-890
34. Schwartz D., Decker C.J., and Parker R. The enhancer of decapping proteins, Edc1p and Edc2p, bind RNA and stimulate the activity of the decapping enzyme. RNA 9 (2003) 239-251
35. Gallie D.R., and Tanguay R. Poly(A) binds to initiation factors and increases cap-dependent translation in vitro. J. Biol. Chem. 269 (1994) 17166-17173
36. Jacobson A., and Favreau M. Possible involvement of poly(A) in protein synthesis. Nucleic Acids Res. 11 (1983) 6353-6368
37. Munroe D., and Jacobson A. mRNA poly(A) tail, a 3′ enhancer of translational initiation. Mol. Cell. Biol. 10 (1990) 3441-3455
38. Borman A.M., Michel Y.M., Malnou C.E., and Kean K.M. Free poly(A) stimulates capped mRNA translation in vitro through the eIF4G-poly(A)-binding protein interaction. J. Biol. Chem. 277 (2002) 36818-36824
39. Malone R.W., Felgner P.L., and Verma I.M. Cationic liposome-mediated RNA transfection. Proc. Natl. Acad. Sci. USA 86 (1989) 6077-6081
40. Fisher K.J., and Wilson J.M. The transmembrane domain of diphtheria toxin improves molecular conjugate gene transfer. Biochem. J. 321 Pt. 1 (1997) 49-58
41. Zohra F.T., Chowdhury E.H., Tada S., Hoshiba T., and Akaike T. Effective delivery with enhanced translational activity synergistically accelerates mRNA-based transfection. Biochem. Biophys. Res. Commun. 358 (2007) 373-378
42. Bettinger T., Carlisle R.C., Read M.L., Ogris M., and Seymour L.W. Peptide-mediated RNA delivery: a novel approach for enhanced transfection of primary and post-mitotic cells. Nucleic Acids Res. 29 (2001) 3882-3891
43. Lu D., Benjamin R., Kim M., Conry R.M., and Curiel D.T. Optimization of methods to achieve mRNA-mediated transfection of tumor cells in vitro and in vivo employing cationic liposome vectors. Cancer Gene Ther. 1 (1994) 245-252
44. Read M.L., Singh S., Ahmed Z., Stevenson M., Briggs S.S., Oupicky D., Barrett L.B., Spice R., Kendall M., Berry M., Preece J.A., Logan A., and Seymour L.W. A versatile reducible polycation-based system for efficient delivery of a broad range of nucleic acids. Nucleic Acids Res. 33 (2005) e86
45. Huth S., Hoffmann F., von Gersdorff K., Laner A., Reinhardt D., Rosenecker J., and Rudolph C. Interaction of polyamine gene vectors with RNA leads to the dissociation of plasmid DNA-carrier complexes. J. Gene Med. 8 (2006) 1416-1424
46. Van Tendeloo V.F., Ponsaerts P., Lardon F., Nijs G., Lenjou M., Van Broeckhoven C., Van Bockstaele D.R., and Berneman Z.N. Highly efficient gene delivery by mRNA electroporation in human hematopoietic cells: superiority to lipofection and passive pulsing of mRNA and to electroporation of plasmid cDNA for tumor antigen loading of dendritic cells. Blood 98 (2001) 49-56
47. Ponsaerts P., van der Sar S., Van Tendeloo V.F., Jorens P.G., Berneman Z.N., and Singh P.B. Highly efficient mRNA-based gene transfer in feeder-free cultured H9 human embryonic stem cells. Cloning Stem Cells 6 (2004) 211-216
48. Strauss J.H., and Strauss E.G. The alphaviruses: gene expression, replication, and evolution. Microbiol. Rev. 58 (1994) 491-562
49. Charles P.C., Brown K.W., Davis N.L., Hart M.K., and Johnston R.E. Mucosal immunity induced by parenteral immunization with a live attenuated Venezuelan equine encephalitis virus vaccine candidate. Virology 228 (1997) 153-160
50. Agapov E.V., Frolov I., Lindenbach B.D., Pragai B.M., Schlesinger S., and Rice C.M. Noncytopathic Sindbis virus RNA vectors for heterologous gene expression. Proc. Natl. Acad. Sci. USA 95 (1998) 12989-12994
51. Bitzer M., Armeanu S., Lauer U.M., and Neubert W.J. Sendai virus vectors as an emerging negative-strand RNA viral vector system. J. Gene Med. 5 (2003) 543-553
52. Agungpriyono D.R., Yamaguchi R., Uchida K., Tohya Y., Kato A., Nagai Y., Asakawa M., and Tateyama S. Green fluorescent protein gene insertion of Sendai Virus infection in nude mice: possibility as an infection tracer. J. Vet. Med. Sci. 62 (2000) 223-228
53. Hasan M.K., Kato A., Shioda T., Sakai Y., Yu D., and Nagai Y. Creation of an infectious recombinant Sendai virus expressing the firefly luciferase gene from the 3′ proximal first locus. J. Gen. Virol. 78 Pt. 11 (1997) 2813-2820
54. Yonemitsu Y., Kitson C., Ferrari S., Farley R., Griesenbach U., Judd D., Steel R., Scheid P., Zhu J., Jeffery P.K., Kato A., Hasan M.K., Nagai Y., Masaki I., Fukumura M., Hasegawa M., Geddes D.M., and Alton E.W. Efficient gene transfer to airway epithelium using recombinant Sendai virus. Nat. Biotechnol. 18 (2000) 970-973
55. Tokusumi T., Iida A., Hirata T., Kato A., Nagai Y., and Hasegawa M. Recombinant Sendai viruses expressing different levels of a foreign reporter gene. Virus Res. 86 (2002) 33-38
56. Bitzer M., Ungerechts G., Bossow S., Graepler F., Sedlmeier R., Armeanu S., Bernloehr C., Spiegel M., Gross C.D., Gregor M., Neubert W.J., and Lauer U.M. Negative-strand RNA viral vectors: intravenous application of Sendai virus vectors for the systemic delivery of therapeutic genes. Mol. Ther. 7 (2003) 210-217
57. Griesenbach U., Cassady R.L., Ferrari S., Fukumura M., Muller C., Schmitt E., Zhu J., Jeffery P.K., Nagai Y., Geddes D.M., Hasegawa M., and Alton E.W. The nasal epithelium as a factory for systemic protein delivery. Mol. Ther. 5 (2002) 98-103
58. Shiotani A., Fukumura M., Maeda M., Hou X., Inoue M., Kanamori T., Komaba S., Washizawa K., Fujikawa S., Yamamoto T., Kadono C., Watabe K., Fukuda H., Saito K., Sakai Y., Nagai Y., Kanzaki J., and Hasegawa M. Skeletal muscle regeneration after insulin-like growth factor I gene transfer by recombinant Sendai virus vector. Gene Ther. 8 (2001) 1043-1050
59. Iwadate Y., Inoue M., Saegusa T., Tokusumi Y., Kinoh H., Hasegawa M., Tagawa M., Yamaura A., and Shimada H. Recombinant Sendai virus vector induces complete remission of established brain tumors through efficient interleukin-2 gene transfer in vaccinated rats. Clin. Cancer Res. 11 (2005) 3821-3827
60. Miyoshi M., Nakano Y., Sakaguchi T., Ogi H., Oda N., Suenari K., Kiyotani K., Ozono R., Oshima T., Yoshida T., and Chayama K. Gene delivery of paraoxonase-1 inhibits neointimal hyperplasia after arterial balloon-injury in rabbits fed a high-fat diet. Hypertens. Res. 30 (2007) 85-91
61. Ferrari S., Griesenbach U., Iida A., Farley R., Wright A.M., Zhu J., Munkonge F.M., Smith S.N., You J., Ban H., Inoue M., Chan M., Singh C., Verdon B., Argent B.E., Wainwright B., Jeffery P.K., Geddes D.M., Porteous D.J., Hyde S.C., Gray M.A., Hasegawa M., and Alton E.W. Sendai virus-mediated CFTR gene transfer to the airway epithelium. Gene Ther. 14 (2007) 1371-1379
62. Ballas Z.K., Rasmussen W.L., and Krieg A.M. Induction of NK activity in murine and human cells by CpG motifs in oligodeoxynucleotides and bacterial DNA. J. Immunol. 157 (1996) 1840-1845
63. Halpern M.D., Kurlander R.J., and Pisetsky D.S. Bacterial DNA induces murine interferon-gamma production by stimulation of interleukin-12 and tumor necrosis factor-alpha. Cell Immunol. 167 (1996) 72-78
64. Krieg A.M., Yi A.K., Matson S., Waldschmidt T.J., Bishop G.A., Teasdale R., Koretzky G.A., and Klinman D.M. CpG motifs in bacterial DNA trigger direct B-cell activation. Nature 374 (1995) 546-549
65. Tan Y., Li S., Pitt B.R., and Huang L. The inhibitory role of CpG immunostimulatory motifs in cationic lipid vector-mediated transgene expression in vivo. Hum. Gene Ther. 10 (1999) 2153-2161
66. Freimark B.D., Blezinger H.P., Florack V.J., Nordstrom J.L., Long S.D., Deshpande D.S., Nochumson S., and Petrak K.L. Cationic lipids enhance cytokine and cell influx levels in the lung following administration of plasmid: cationic lipid complexes. J. Immunol. 160 (1998) 4580-4586
67. Li S., Wu S.P., Whitmore M., Loeffert E.J., Wang L., Watkins S.C., Pitt B.R., and Huang L. Effect of immune response on gene transfer to the lung via systemic administration of cationic lipidic vectors. Am. J. Physiol. 276 (1999) L796-L804
68. Yew N.S., Zhao H., Wu I.H., Song A., Tousignant J.D., Przybylska M., and Cheng S.H. Reduced inflammatory response to plasmid DNA vectors by elimination and inhibition of immunostimulatory CpG motifs. Mol. Ther. 1 (2000) 255-262
69. Gautam A., Densmore C.L., and Waldrep J.C. Pulmonary cytokine responses associated with PEI-DNA aerosol gene therapy. Gene Ther. 8 (2001) 254-257
70. Kawakami S., Ito Y., Charoensit P., Yamashita F., and Hashida M. Evaluation of proinflammatory cytokine production induced by linear and branched polyethylenimine/plasmid DNA complexes in mice. J. Pharmacol. Exp. Ther. 317 (2006) 1382-1390
71. Chuang T.H., and Ulevitch R.J. Cloning and characterization of a sub-family of human toll-like receptors: hTLR7, hTLR8 and hTLR9. Eur. Cytokine Netw. 11 (2000) 372-378
72. Du X., Poltorak A., Wei Y., and Beutler B. Three novel mammalian toll-like receptors: gene structure, expression, and evolution. Eur. Cytokine Netw. 11 (2000) 362-371
73. Tabeta K., Georgel P., Janssen E., Du X., Hoebe K., Crozat K., Mudd S., Shamel L., Sovath S., Goode J., Alexopoulou L., Flavell R.A., and Beutler B. Toll-like receptors 9 and 3 as essential components of innate immune defense against mouse cytomegalovirus infection. Proc. Natl. Acad. Sci. USA 101 (2004) 3516-3521
74. Akira S., Takeda K., and Kaisho T. Toll-like receptors: critical proteins linking innate and acquired immunity. Nat. Immunol. 2 (2001) 675-680
75. Janeway Jr. C.A., and Medzhitov R. Innate immune recognition. Annu. Rev. Immunol. 20 (2002) 197-216
76. Medzhitov R. Toll-like receptors and innate immunity. Nat. Rev. Immunol. 1 (2001) 135-145
77. Csete M., and Doyle J. Bow ties, metabolism and disease. Trends Biotechnol. 22 (2004) 446-450
78. Ahmad-Nejad P., Hacker H., Rutz M., Bauer S., Vabulas R.M., and Wagner H. Bacterial CpG-DNA and lipopolysaccharides activate Toll-like receptors at distinct cellular compartments. Eur. J. Immunol. 32 (2002) 1958-1968
79. Heil F., Ahmad-Nejad P., Hemmi H., Hochrein H., Ampenberger F., Gellert T., Dietrich H., Lipford G., Takeda K., Akira S., Wagner H., and Bauer S. The Toll-like receptor 7 (TLR7)-specific stimulus loxoribine uncovers a strong relationship within the TLR7, 8 and 9 subfamily. Eur. J. Immunol. 33 (2003) 2987-2997
80. Matsumoto M., Funami K., Tanabe M., Oshiumi H., Shingai M., Seto Y., Yamamoto A., and Seya T. Subcellular localization of Toll-like receptor 3 in human dendritic cells. J. Immunol. 171 (2003) 3154-3162
81. Alexopoulou L., Holt A.C., Medzhitov R., and Flavell R.A. Recognition of double-stranded RNA and activation of NF-kappaB by Toll-like receptor 3. Nature 413 (2001) 732-738
82. Kariko K., Bhuyan P., Capodici J., and Weissman D. Small interfering RNAs mediate sequence-independent gene suppression and induce immune activation by signaling through toll-like receptor 3. J. Immunol. 172 (2004) 6545-6549
83. Heil F., Hemmi H., Hochrein H., Ampenberger F., Kirschning C., Akira S., Lipford G., Wagner H., and Bauer S. Species-specific recognition of single-stranded RNA via toll-like receptor 7 and 8. Science 303 (2004) 1526-1529
84. Hemmi H., Takeuchi O., Kawai T., Kaisho T., Sato S., Sanjo H., Matsumoto M., Hoshino K., Wagner H., Takeda K., and Akira S. A toll-like receptor recognizes bacterial DNA. Nature 408 (2000) 740-745
85. Krug A., French A.R., Barchet W., Fischer J.A., Dzionek A., Pingel J.T., Orihuela M.M., Akira S., Yokoyama W.M., and Colonna M. TLR9-dependent recognition of MCMV by IPC and DC generates coordinated cytokine responses that activate antiviral NK cell function. Immunity 21 (2004) 107-119
86. Honda K., and Taniguchi T. IRFs: master regulators of signalling by Toll-like receptors and cytosolic pattern-recognition receptors. Nat. Rev. Immunol. 6 (2006) 644-658
87. Van Tendeloo V.F., Ponsaerts P., and Berneman Z.N. mRNA-based gene transfer as a tool for gene and cell therapy. Curr. Opin. Mol. Ther. 9 (2007) 423-431
88. Banchereau J., and Palucka A.K. Dendritic cells as therapeutic vaccines against cancer. Nat. Rev. Immunol. 5 (2005) 296-306
89. Grunebach F., Muller M.R., and Brossart P. RNA transfection of dendritic cells. Methods Mol. Med. 109 (2005) 47-54
90. Gilboa E., and Vieweg J. Cancer immunotherapy with mRNA-transfected dendritic cells. Immunol. Rev. 199 (2004) 251-263
91. Bacci A., Montagnoli C., Perruccio K., Bozza S., Gaziano R., Pitzurra L., Velardi A., d'Ostiani C.F., Cutler J.E., and Romani L. Dendritic cells pulsed with fungal RNA induce protective immunity to Candida albicans in hematopoietic transplantation. J. Immunol. 168 (2002) 2904-2913
92. Yu H., Babiuk L.A., and van Drunen Littel-van den Hurk S. Immunity and protection by adoptive transfer of dendritic cells transfected with hepatitis C NS3/4A mRNA. Vaccine 25 (2007) 1701-1711
93. Van Gulck E.R., Ponsaerts P., Heyndrickx L., Vereecken K., Moerman F., De Roo A., Colebunders R., Van den Bosch G., Van Bockstaele D.R., Van Tendeloo V.F., Allard S., Verrier B., Maranon C., Hoeffel G., Hosmalin A., Berneman Z.N., and Vanham G. Efficient stimulation of HIV-1-specific T cells using dendritic cells electroporated with mRNA encoding autologous HIV-1 Gag and Env proteins. Blood 107 (2006) 1818-1827
94. Zhou X., Berglund P., Rhodes G., Parker S.E., Jondal M., and Liljestrom P. Self-replicating Semliki Forest virus RNA as recombinant vaccine. Vaccine 12 (1994) 1510-1514
95. Herweijer H., Latendresse J.S., Williams P., Zhang G., Danko I., Schlesinger S., and Wolff J.A. A plasmid-based self-amplifying Sindbis virus vector. Hum. Gene Ther. 6 (1995) 1161-1167
96. Schlesinger S. Alphavirus vectors: development and potential therapeutic applications. Expert Opin. Biol. Ther. 1 (2001) 177-191
97. Leitner W.W., Hwang L.N., deVeer M.J., Zhou A., Silverman R.H., Williams B.R., Dubensky T.W., Ying H., and Restifo N.P. Alphavirus-based DNA vaccine breaks immunological tolerance by activating innate antiviral pathways. Nat. Med. 9 (2003) 33-39
98. Probst J., Weide B., Scheel B., Pichler B.J., Hoerr I., Rammensee H.G., and Pascolo S. Spontaneous cellular uptake of exogenous messenger RNA in vivo is nucleic acid-specific, saturable and ion dependent. Gene Ther. 14 (2007) 1175-1180
99. Szczepek M., Brondani V., Buchel J., Serrano L., Segal D.J., and Cathomen T. Structure-based redesign of the dimerization interface reduces the toxicity of zinc-finger nucleases. Nat. Biotechnol. 25 (2007) 786-793